Patent · US Active

Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

US10092564B2 · kind B2 · utility

8Cited by

1References

20Claims

0Family size

Assignee

AB SCIENCE · FR

Inventors

Alain Moussy · Paris, FR
Jean-Pierre Kinet · Bethesda, US
Colin MANSFIELD · Stowmarket, GB

Key dates

Filing date	Mar 24, 2017
Grant date	Oct 9, 2018
Priority date	—
Expiry date	Mar 24, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.